Share on StockTwits

Kindred Biosciences (NYSE:KIN) posted its quarterly earnings results on Thursday. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by $0.07, AR Network reports.

On the ratings front, analysts at Craig Hallum initiated coverage on shares of Kindred Biosciences in a research note on Friday, May 23rd. They set a “buy” rating on the stock. Three equities research analysts have rated the stock with a buy rating, Kindred Biosciences has a consensus rating of “Buy” and an average price target of $26.33.

Kindred Biosciences (NYSE:KIN) opened at 15.82 on Thursday. Kindred Biosciences has a one year low of $8.75 and a one year high of $26.99. The stock’s 50-day moving average is $16.49 and its 200-day moving average is $18.1. The company’s market cap is $311.3 million.

Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company focused on pets.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.